{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T22:43:31Z","timestamp":1790981011086,"version":"4.1.0"},"reference-count":83,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,5,12]],"date-time":"2020-05-12T00:00:00Z","timestamp":1589241600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012754","name":"Horizon Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012754","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.semarthrit.2020.04.011","type":"journal-article","created":{"date-parts":[[2020,6,30]],"date-time":"2020-06-30T14:32:16Z","timestamp":1593527536000},"page":"S31-S38","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":57,"special_numbering":"S","title":["Pegloticase treatment of chronic refractory gout: Update on efficacy and safety"],"prefix":"10.1016","volume":"50","author":[{"given":"Naomi","family":"Schlesinger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter E.","family":"Lipsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semarthrit.2020.04.011_bib0001","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1080\/14656566.2018.1498842","article-title":"Febuxostat for the treatment of hyperuricaemia in gout","volume":"19","author":"Robinson","year":"2018","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.semarthrit.2020.04.011_bib0002","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1080\/14740338.2017.1284199","article-title":"The safety of treatment options available for gout","volume":"16","author":"Schlesinger","year":"2017","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.semarthrit.2020.04.011_bib0003","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.3899\/jrheum.080814","article-title":"Clinical efficacy and safety of successful long-term urate lowering with febuxostat or allopurinol in subjects with gout","volume":"36","author":"Becker","year":"2009","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.04.011_bib0004","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1007\/s12325-012-0059-z","article-title":"Evaluation and treatment of gout as a chronic disease","volume":"29","author":"Perez-Ruiz","year":"2012","journal-title":"Adv Ther"},{"key":"10.1016\/j.semarthrit.2020.04.011_bib0005","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1185\/03007995.2010.533647","article-title":"Chronic gout: epidemiology, disease progression, treatment and disease burden","volume":"26","author":"Brook","year":"2010","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.semarthrit.2020.04.011_bib0006","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1001\/jama.2011.1169","article-title":"Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials","volume":"306","author":"Sundy","year":"2011","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.semarthrit.2020.04.011_bib0007","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1002\/art.40807","article-title":"Contemporary prevalence of gout and hyperuricemia in the United States and decadal trends: The National Health and Nutrition Examination Survey, 2007-2016","volume":"71","author":"Chen-Xu","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.04.011_bib0008","doi-asserted-by":"crossref","first-page":"e157","DOI":"10.1097\/MJT.0b013e31820543c5","article-title":"Comorbidity burden, healthcare resource utilization, and costs in chronic gout patients refractory to conventional urate-lowering therapy","volume":"19","author":"Wu","year":"2012","journal-title":"Am J Ther"},{"key":"10.1016\/j.semarthrit.2020.04.011_bib0009","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1002\/art.30520","article-title":"Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008","volume":"63","author":"Zhu","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2020.04.011_bib0010","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1093\/molbev\/msw116","article-title":"Coevolution of URAT1 and uricase during primate evolution: Implications for serum urate homeostasis and gout","volume":"33","author":"Tan","year":"2016","journal-title":"Mol Biol Evol"},{"key":"10.1016\/j.semarthrit.2020.04.011_bib0011","doi-asserted-by":"crossref","first-page":"9412","DOI":"10.1073\/pnas.86.23.9412","article-title":"Urate oxidase: primary structure and evolutionary implications","volume":"86","author":"Wu","year":"1989","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.semarthrit.2020.04.011_bib0012","doi-asserted-by":"crossref","first-page":"83","DOI":"10.7150\/ijms.4.83","article-title":"Rasburicase represents a new tool for hyperuricemia in tumor lysis syndrome and in gout","volume":"4","author":"Cammalleri","year":"2007","journal-title":"Int J Med Sci"},{"key":"10.1016\/j.semarthrit.2020.04.011_bib0013","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.addr.2007.06.011","article-title":"PEG-uricase in the management of treatment-resistant gout and hyperuricemia","volume":"60","author":"Sherman","year":"2008","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.semarthrit.2020.04.011_bib0014","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1002\/art.22403","article-title":"Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout","volume":"56","author":"Sundy","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2020.04.011_bib0015","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1681\/ASN.V1251001","article-title":"Diabetes insipidus in uricase-deficient mice: a model for evaluating therapy with poly(ethylene glycol)-modified uricase","volume":"12","author":"Kelly","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semarthrit.2020.04.011_bib0016","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/nrd3349","article-title":"Pegloticase","volume":"10","author":"Schlesinger","year":"2011","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.semarthrit.2020.04.011_bib0017","doi-asserted-by":"crossref","first-page":"R60","DOI":"10.1186\/ar4497","article-title":"Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout","volume":"16","author":"Lipsky","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2020.04.011_bib0018","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1097\/RHU.0000000000000200","article-title":"Infusion-related reactions with pegloticase, a recombinant uricase for the treatment of chronic gout refractory to conventional therapy","volume":"20","author":"Baraf","year":"2014","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.04.011_bib0019","doi-asserted-by":"crossref","first-page":"722","DOI":"10.2146\/ajhp130571","article-title":"Investigation of pegloticase-associated adverse events from a nationwide reporting system database","volume":"71","author":"Gentry","year":"2014","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.semarthrit.2020.04.011_bib0020","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1186\/s13075-017-1396-8","article-title":"Frequency, distribution and immunologic nature of infusion reactions in subjects receiving pegloticase for chronic refractory gout","volume":"19","author":"Calabrese","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2020.04.011_bib0021","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s12245-009-0093-z","article-title":"Visual representation of National Institute of Allergy and Infectious Disease and Food Allergy and Anaphylaxis Network criteria for anaphylaxis","volume":"2","author":"Manivannan","year":"2009","journal-title":"Int J Emerg Med"},{"key":"10.1016\/j.semarthrit.2020.04.011_bib0022","unstructured":"Krystexxa Prescribing Information. 2012. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/125293s034lbl.pdf"},{"key":"10.1016\/j.semarthrit.2020.04.011_bib0023","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s40744-019-0151-9","article-title":"Use of Pre-Infusion Serum Uric Acid Levels as a Biomarker for Infusion Reaction Risk in Patients on Pegloticase","volume":"6","author":"Keenan","year":"2019","journal-title":"Rheumatol Ther"},{"issue":"suppl 10","key":"10.1016\/j.semarthrit.2020.04.011_bib0024","article-title":"Initial Results of a Clinical Study to Determine Whether a Tolerizing Regimen of Pegloticase Can Increase the Frequency of Subjects Having Sustained Lowering of Serum Urate [abstract]","volume":"69","author":"Saag","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.04.011_bib0025","article-title":"Dissociation between clinical benefit and persistent urate lowering in patients with chronic refractory gout treated with Pegloticase","author":"Pillinger","year":"2019","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.04.011_bib0026","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1002\/art.22232","article-title":"Using serum urate levels to determine the period free of gouty symptoms after withdrawal of long-term urate-lowering therapy: a prospective study","volume":"55","author":"Perez-Ruiz","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2020.04.011_bib0027","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/kez030","article-title":"Immunogenicity of biologic agents in juvenile idiopathic arthritis: a systematic review and meta-analysis","author":"Doeleman","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2020.04.011_bib0028","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1517\/14740338.2016.1112375","article-title":"Immunogenicity of infliximab and adalimumab: what is its role in hypersensitivity and modulation of therapeutic efficacy and safety","volume":"15","author":"Murdaca","year":"2016","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.semarthrit.2020.04.011_bib0029","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.phrs.2016.07.015","article-title":"Pharmacokinetics interactions of monoclonal antibodies","volume":"111","author":"Ferri","year":"2016","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.semarthrit.2020.04.011_bib0030","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1093\/rheumatology\/kev277","article-title":"Immunogenicity of biologic agents in rheumatoid arthritis patients: lessons for clinical practice","volume":"55","author":"Schaeverbeke","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2020.04.011_bib0031","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1093\/rheumatology\/ker124","article-title":"Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis","volume":"50","author":"Pascual-Salcedo","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2020.04.011_bib0032","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.semarthrit.2018.11.006","article-title":"Recapture and improved outcome of pegloticase response with methotrexate-A report of two cases and review of the literature","volume":"49","author":"Bessen","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2020.04.011_bib0033","doi-asserted-by":"crossref","first-page":"R63","DOI":"10.1186\/ar4500","article-title":"Induced and pre-existing anti-polyethylene glycol antibody in a trial of every 3-week dosing of pegloticase for refractory gout, including in organ transplant recipients","volume":"16","author":"Hershfield","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2020.04.011_bib0034","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.semarthrit.2016.09.007","article-title":"Pegloticase failure and a possible solution: Immunosuppression to prevent intolerance and inefficacy in patients with gout","volume":"46","author":"Berhanu","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2020.04.011_bib0035","unstructured":"ClinicalTrials.gov. REduCing immunogenicity to Pegloticase (RECIPE) study (RECIPE) (NCT03303989). 2019a. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03303989"},{"key":"10.1016\/j.semarthrit.2020.04.011_bib0036","unstructured":"ClinicalTrials.gov. Study of Pegloticase (KRYSTEXXA\u00ae) plus methotrexate in patients with uncontrolled gout (MIRROR OL) (NCT03635957). 2019b. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03635957"},{"key":"10.1016\/j.semarthrit.2020.04.011_bib0037","unstructured":"ClinicalTrials.gov. Tolerization Reduces Intolerance to Pegloticase and Prolongs the Urate Lowering Effect (TRIPLE) (NCT02598596). 2019c. Available at: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02598596?term=pegloticase\u00b1triple&rank=1"},{"key":"10.1016\/j.semarthrit.2020.04.011_bib0038","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/art.39840","article-title":"Lesinurad combined with allopurinol: a randomized, double-blind, placebo-controlled study in gout patients with an inadequate response to standard-of-care allopurinol (a US-based study)","volume":"69","author":"Saag","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"Suppl 2","key":"10.1016\/j.semarthrit.2020.04.011_bib0039","article-title":"The regimen of Pegloticase administration can increase the frequency of subjects having sustained lowering of serum urate","volume":"77","author":"Saag","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2020.04.011_bib0040","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.berh.2015.04.025","article-title":"Molecular mechanisms of pain in crystal-induced arthritis","volume":"29","author":"Ramonda","year":"2015","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"Suppl 2","key":"10.1016\/j.semarthrit.2020.04.011_bib0041","article-title":"The frequency of flares in subjects with chronic refractory gout treated with pegloticase is related to variation in the level of plasma urate","volume":"77","author":"Calabrese","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2020.04.011_bib0042","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1471-2318-12-11","article-title":"The efficacy and safety of febuxostat for urate lowering in gout patients \u226565 years of age","volume":"12","author":"Jackson","year":"2012","journal-title":"BMC Geriatr"},{"key":"10.1016\/j.semarthrit.2020.04.011_bib0043","doi-asserted-by":"crossref","first-page":"R63","DOI":"10.1186\/ar2978","article-title":"The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial","volume":"12","author":"Becker","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2020.04.011_bib0044","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1002\/art.40159","article-title":"Lesinurad, a selective uric acid reabsorption inhibitor, in combination with febuxostat in patients with tophaceous gout: Findings of a phase III clinical trial","volume":"69","author":"Dalbeth","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.04.011_bib0045","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/1756-185X.12648","article-title":"A phase 3, multicenter, randomized, allopurinol-controlled study assessing the safety and efficacy of oral febuxostat in Chinese gout patients with hyperuricemia","volume":"18","author":"Xu","year":"2015","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.semarthrit.2020.04.011_bib0046","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/acr.21772","article-title":"2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia","volume":"64","author":"Khanna","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.semarthrit.2020.04.011_bib0047","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/annrheumdis-2016-209707","article-title":"2016 updated EULAR evidence-based recommendations for the management of gout","volume":"76","author":"Richette","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2020.04.011_bib0048","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1136\/annrheumdis-2013-203325","article-title":"Multinational evidence-based recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative","volume":"73","author":"Sivera","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2020.04.011_bib0049","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.3899\/jrheum.111375","article-title":"Improved health-related quality of life and physical function in patients with refractory chronic gout following treatment with pegloticase: evidence from phase III randomized controlled trials","volume":"39","author":"Strand","year":"2012","journal-title":"J Rheumatol"},{"issue":"Suppl 2","key":"10.1016\/j.semarthrit.2020.04.011_bib0050","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1136\/annrheumdis-2017-eular.4119","article-title":"Progressive clinical benefit in chronic refractory gout patients achieving a persistent urate lowering effect from pegloticase treatment","volume":"76","author":"Khanna","year":"2017","journal-title":"Ann Rheumatic Dis"},{"key":"10.1016\/j.semarthrit.2020.04.011_bib0051","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/acr.22059","article-title":"Exploratory study of radiographic change in patients with tophaceous gout treated with intensive urate-lowering therapy","volume":"66","author":"Dalbeth","year":"2014","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.semarthrit.2020.04.011_bib0052","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1080\/00325481.2016.1221732","article-title":"Overview of serum uric acid treatment targets in gout: why less than 6mg\/dL","volume":"128","author":"Ruoff","year":"2016","journal-title":"Postgrad Med"},{"key":"10.1016\/j.semarthrit.2020.04.011_bib0053","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1093\/rheumatology\/kew383","article-title":"Relationship of bone erosion with the urate and soft tissue components of the tophus in gout: a dual energy computed tomography study","volume":"56","author":"Sapsford","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2020.04.011_bib0054","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1002\/art.27356","article-title":"Cellular characterization of the gouty tophus: a quantitative analysis","volume":"62","author":"Dalbeth","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2020.04.011_bib0055","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1146\/annurev-immunol-041015-055539","article-title":"Crystal formation in inflammation","volume":"34","author":"Franklin","year":"2016","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.semarthrit.2020.04.011_bib0056","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1093\/rheumatology\/kem246","article-title":"Tophaceous joint disease strongly predicts hand function in patients with gout","volume":"46","author":"Dalbeth","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2020.04.011_bib0057","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1093\/rheumatology\/kem150","article-title":"Is gout associated with reduced quality of life? A case-control study","volume":"46","author":"Roddy","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2020.04.011_bib0058","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1080\/00325481.2016.1113840","article-title":"A world of hurt: failure to achieve treatment goals in patients with gout requires a paradigm shift","volume":"128","author":"Khanna","year":"2016","journal-title":"Postgrad Med"},{"key":"10.1016\/j.semarthrit.2020.04.011_bib0059","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1186\/s13075-018-1782-x","article-title":"Tophus resolution in patients with chronic refractory gout who have persistent urate-lowering responses to pegloticase","volume":"20","author":"Mandell","year":"2018","journal-title":"Arthritis Res Ther"},{"issue":"Suppl 10","key":"10.1016\/j.semarthrit.2020.04.011_bib0060","article-title":"Predictors of mortality in people with recent onset of gout: a prospective observational study. 2016 ACR\/ARHP Annual Meeting, September 28, 2016","volume":"68","author":"Vincent","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.04.011_bib0061","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1002\/art.24209","article-title":"Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial","volume":"59","author":"Schumacher","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2020.04.011_bib0062","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1056\/NEJMoa050373","article-title":"Febuxostat compared with allopurinol in patients with hyperuricemia and gout","volume":"353","author":"Becker","year":"2005","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.semarthrit.2020.04.011_bib0063","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1002\/art.23007","article-title":"Lowering serum uric acid levels: What is the optimal target for improving clinical outcomes in gout?","volume":"15","author":"Perez Ruiz","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2020.04.011_bib0064","doi-asserted-by":"crossref","first-page":"R137","DOI":"10.1186\/ar4318","article-title":"Tophus burden reduction with pegloticase: results from phase 3 randomized trials and open-label extension in patients with chronic gout refractory to conventional therapy","volume":"15","author":"Baraf","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2020.04.011_bib0065","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2015-000075","article-title":"Tophus resolution with pegloticase: a prospective dual-energy CT study","volume":"1","author":"Araujo","year":"2015","journal-title":"RMD Open"},{"key":"10.1016\/j.semarthrit.2020.04.011_bib0066","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1002\/acr.22741","article-title":"Development of preliminary remission criteria for gout using Delphi and 1000Minds consensus exercises","volume":"68","author":"De Lautour","year":"2016","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.semarthrit.2020.04.011_bib0067","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1002\/acr2.1025","article-title":"Evaluation of Proposed Criteria for Remission and Evidence Based Development of Criteria for Complete Response in Patients with Chronic Refractory Gout","volume":"1","author":"Schlesinger","year":"2019","journal-title":"ACR Open Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.04.011_bib0068","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1093\/rheumatology\/kes211","article-title":"Gout and its comorbidities: implications for therapy","volume":"52","author":"Stamp","year":"2013","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2020.04.011_bib0069","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.amjmed.2011.09.033","article-title":"Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007-2008","volume":"125","author":"Zhu","year":"2012","journal-title":"Am J Med"},{"key":"10.1016\/j.semarthrit.2020.04.011_bib0070","doi-asserted-by":"crossref","first-page":"e56546","DOI":"10.1371\/journal.pone.0056546","article-title":"Dose-response association of uncontrolled blood pressure and cardiovascular disease risk factors with hyperuricemia and gout","volume":"8","author":"Juraschek","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.semarthrit.2020.04.011_bib0071","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1161\/01.HYP.0000150784.92944.9a","article-title":"Relations of serum uric acid to longitudinal blood pressure tracking and hypertension incidence","volume":"45","author":"Sundstr\u00f6m","year":"2005","journal-title":"Hypertension"},{"key":"10.1016\/j.semarthrit.2020.04.011_bib0072","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/BOR.0b013e32835cedd4","article-title":"Hypertension, its treatment, hyperuricaemia and gout","volume":"25","author":"Gibson","year":"2013","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.04.011_bib0073","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.2215\/CJN.11451210","article-title":"A randomized study of allopurinol on endothelial function and estimated glomular filtration rate in asymptomatic hyperuricemic subjects with normal renal function","volume":"6","author":"Kanbay","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.semarthrit.2020.04.011_bib0074","first-page":"542129","article-title":"The Effects of allopurinol on the carotid intima-media thickness in patients with type 2 diabetes and asymptomatic hyperuricemia: A three-year randomized parallel-controlled study","author":"Liu","year":"2015","journal-title":"Intern Med"},{"key":"10.1016\/j.semarthrit.2020.04.011_bib0075","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.3346\/jkms.2014.29.8.1077","article-title":"Four-week effects of allopurinol and febuxostat treatments on blood pressure and serum creatinine level in gouty men","volume":"29","author":"Kim","year":"2014","journal-title":"J Korean Med Sci"},{"key":"10.1016\/j.semarthrit.2020.04.011_bib0076","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1161\/HYPERTENSIONAHA.119.12727","article-title":"Pegloticase treatment significantly decreases blood pressure in patients with chronic gout","volume":"74","author":"Johnson","year":"2019","journal-title":"Hypertension"},{"key":"10.1016\/j.semarthrit.2020.04.011_bib0077","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s13075-015-0610-9","article-title":"Gout and risk of chronic kidney disease and nephrolithiasis: meta-analysis of observational studies","volume":"17","author":"Roughley","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2020.04.011_bib0078","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/s40261-015-0349-8","article-title":"Effect of Febuxostat, a Xanthine oxidase inhibitor, on cardiovascular risk in hyperuricemic patients with hypertension: A prospective, open-label, pilot study","volume":"35","author":"Tani","year":"2015","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.semarthrit.2020.04.011_bib0079","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1097\/RHU.0b013e318204aab4","article-title":"Renal function in gout: long-term treatment effects of febuxostat","volume":"17","author":"Whelton","year":"2011","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.04.011_bib0080","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/hr.2016.139","article-title":"Effective uric acid-lowering treatment for hypertensive patients with hyperuricemia","volume":"40","author":"Ohta","year":"2017","journal-title":"Hypertens Res"},{"key":"10.1016\/j.semarthrit.2020.04.011_bib0081","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1053\/j.ajkd.2015.05.017","article-title":"Efficacy of Febuxostat for slowing the GFR decline in patients with CKD and asymptomatic Hyperuricemia: A 6-month, double-blind, randomized, placebo-controlled trial","volume":"66","author":"Sircar","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.semarthrit.2020.04.011_bib0082","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/1756-0500-7-54","article-title":"Effect of pegloticase on renal function in patients with chronic kidney disease: a post hoc subgroup analysis of 2 randomized, placebo-controlled, phase 3 clinical trials","volume":"7","author":"Yood","year":"2014","journal-title":"BMC Res Notes"},{"issue":"Suppl 2","key":"10.1016\/j.semarthrit.2020.04.011_bib0083","first-page":"1370","article-title":"Association of renal dysfunction and development of tophi in subjects with chronic refractory gout and response to treatment with pegloticase","volume":"77","author":"Edwards L","year":"2018","journal-title":"Ann Rheum Dis"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017220301256?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017220301256?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T17:02:35Z","timestamp":1758733355000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017220301256"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":83,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["S0049017220301256"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2020.04.011","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pegloticase treatment of chronic refractory gout: Update on efficacy and safety","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2020.04.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}